

Corporate Profile (As of March 31, 2002)

Establishment:	June 2, 1947
Paid-in capital:	¥3,840 million
Authorized shares:	80,000,000
Outstanding shares:	26,037,375
Number of shareholders:	3,802
Number of employees:	489

Board of Directors and Auditors (As of June 27, 2002)

President:	Shirow Enoki
Senior Managing Director:	Ken Mizutani
Managing Directors:	Katsuyuki Horie Yuichiro Nagata Hideo Takahashi
Director, Senior Counselor:	Kenji Mizutani
Directors:	Fumio Ishii Noriyoshi Numata Shinji Tonomura Toshinori Yagura Shuichi Maeda
Auditors:	Akira Nakagawa Hajime Kikuchi Tatsuo Amiya Eiji Katayama

Company Quality System

A Certification of the Quality System of Seikagaku and the Conformity Assessment Procedure for the European Compliance was performed by the European Notified Body TÜV Product Service GmbH in Deutschland, as documented in the following certificates:

Jan. 1998: EC Certificate (MDD, AnnexII-3)

Feb. 1998: QS Certificate (ISO9001/EN46001/ ISO13485)

Corporate History

- 1947** Kosei Suisan K.K. established.
- 1950** Industrial production begins of chondroitin sulfate as a pharmaceutical.
- 1953** Official name of company changed to K.K. SEIKAGAKU KENKYUSHO.
- 1957** Inauguration of Mucopolysaccharides Study Group.
- 1960** TOKYO RESEARCH INSTITUTE opens. Development and marketing of research biochemicals begins.
- 1962** Official name of company changed to SEIKAGAKU CORPORATION.
- 1967** Korinkaku Symposium for Japanese and international researchers working with mucopolysaccharides.
- 1968** TOKYO RESEARCH INSTITUTE relocated to Higashi-Yamato city.
- 1975** TAKAHAGI PLANT opens.
- 1981** Proteoglycan Meeting convened for international researchers attending the 6th International Glycoconjugates Symposium. World's first endotoxin colorimetry reagent developed and manufactured.
- 1987** Marketing begins for ARTZ[®] and OPEGAN[®]. Joint research with Aichi Medical University established.
- 1989** Company shares registered with the Japan Securities Dealers Association.
- 1990** New wing in the TOKYO RESEARCH INSTITUTE completed.
- 1991** New bulk production facilities in the KURIHAMA PLANT completed.
- 1992** Mizutani Foundation for Glycoscience established. Sales license for ARTZ[®] (ARTZAL[®]) approved in Sweden.
- 1993** New production line for ARTZ Dispo[®] completed, and marketing of the product begins.
- 1994** Sales license for ARTZ[®] approved in Finland.
- 1995** Multipurpose sterile facility at the TOKYO RESEARCH INSTITUTE completed. New upgraded bulk production facility completed at the KURIHAMA PLANT. Sales license for ARTZ[®] approved in Austria. Sales license for ARTZ[®] approved in Italy.
- 1996** The Integrated Quality Control Wing in KURIHAMA PLANT completed.
- 1997** Sales license for ARTZ[®] approved in China. Acquisition of Associates of Cape Cod, Inc. (U.S.A.)
- 1998** QA certification (ISO9001/EN46001) obtained. Sales license for ARTZ[®] approved in Taiwan.
- 1999** Marketing begins for OPEGAN[®]0.6, OPEGAN[®]1.1.
- 2000** Marketing begins for SUPARTZ[®] in EU.
- 2001** Marketing begins for SUPARTZ[®] in U.S.A. and Canada. Third production line at TAKAHAGI PLANT Completed.
- 2002** Marketing begins for Emdogain[®] Gel.